Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smokes an average of at least 10 cigarettes per day during the year prior to enrollment~Exclusion Criteria:~* Interested in quitting smoking within the 3 months following enrollment~* Current unstable medical condition~* Substance abuse within the year prior to enrollment~* Current use of any medications (e.g., psychoactive medications, antihypertensives) that, in the opinion of the investigators, might interfere with study measures or that would be expected to interact with paroxetine (e.g., CYP2D6 substrates)~* Smoking cessation therapy within the 3 months prior to enrollment~* Regular use of any form of tobacco other than cigarettes~* Significant psychiatric disorders as assessed by the PRIME-MD and verified by a clinician~* History of hypersensitivity to any selective serotonin reuptake inhibitor~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Active medication for 4 weeks followed by placebo for 4 weeks
- 2 (Type: EXPERIMENTAL): Placebo for 4 weeks followed by active for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).